Moreover, the 36-month beta value for ANVS is 1.72. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ANVS is 10.24M and currently, short sellers hold a 11.81% of that float. On October 15, 2024, ANVS’s average trading volume was 250.10K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ANVS) stock’s latest price update
The stock price of Annovis Bio Inc (NYSE: ANVS) has surged by 5.06 when compared to previous closing price of 7.51, but the company has seen a -5.28% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-15 that MALVERN, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), announced today the successful outcome of the End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on October 10, 2024. During the meeting, the FDA granted clearance to proceed with pivotal Phase 3 studies, based on the Company’s Phase 2/3 clinical data showing symptomatic improvement in early AD patients. Annovis and the FDA have now aligned on a development path for buntanetap towards the filing of New Drug Applications (NDAs), one for short-term and one for long-term efficacy.
ANVS’s Market Performance
Annovis Bio Inc (ANVS) has seen a -5.28% fall in stock performance for the week, with a -1.62% decline in the past month and a -36.68% plunge in the past quarter. The volatility ratio for the week is 5.99%, and the volatility levels for the past 30 days are at 6.43% for ANVS. The simple moving average for the last 20 days is -2.87% for ANVS stock, with a simple moving average of -16.21% for the last 200 days.
Analysts’ Opinion of ANVS
Many brokerage firms have already submitted their reports for ANVS stocks, with Canaccord Genuity repeating the rating for ANVS by listing it as a “Buy.” The predicted price for ANVS in the upcoming period, according to Canaccord Genuity is $36 based on the research report published on December 29, 2023 of the previous year 2023.
Maxim Group, on the other hand, stated in their research note that they expect to see ANVS reach a price target of $150, previously predicting the price at $45. The rating they have provided for ANVS stocks is “Buy” according to the report published on July 07th, 2021.
ANVS Trading at -5.57% from the 50-Day Moving Average
After a stumble in the market that brought ANVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.92% of loss for the given period.
Volatility was left at 6.43%, however, over the last 30 days, the volatility rate increased by 5.99%, as shares sank -13.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.00% lower at present.
During the last 5 trading sessions, ANVS fell by -9.24%, which changed the moving average for the period of 200-days by -61.35% in comparison to the 20-day moving average, which settled at $8.11. In addition, Annovis Bio Inc saw -57.81% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ANVS
The total capital return value is set at -41.18. Equity return is now at value -453.01, with -308.78 for asset returns.
Currently, EBITDA for the company is -45.04 million with net debt to EBITDA at 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.24.
Conclusion
To wrap up, the performance of Annovis Bio Inc (ANVS) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
